In recent years, the prognosis of colon cancer has shown marked improvement because of advances in diagnosis and treatment, and the 5-year survival rate exceeds 80% in patients undergoing curative resection (Japanese Research Society for Cancer of Colon and Rectum 1990). However, recurrence or metastasis still occurs in about 20% of the patients, and the outcome is not favorable. Among the various cancers of the gastrointestinal tract, colon cancer generally shows a poor response to chemotherapy, and clinical effects of lentinan administration before and after surgery were assessed in the Study I, while lentinan plus IL-2 therapy was studied with respect to the effect on the cytokine balance (Th1/Th2, Tc1 and Tc2) in the Study II. We also discuss the current significance and future prospects of conventional immunotherapy.
Study I: Administration of lentinan before and after surgery
In 1994 and 1995, we performed a randomized comparative study on the histological and clinical effects of lentinan, in an attempt to determine the optimal dose.
The subjects were patients under 75 years of age with Dukes B or C advanced colon cancer which was "curable" on operation. Dukes A patients were excluded since they have a 5-year survival rate of about 95% after surgery alone. The patients were divided into four groups: a control group, and 2mg, 4mg, and 8mg lentinan groups. The lentinan groups were administered lentinan twice about one and two weeks before the operation and then were administered the specified dose from the first week postoperatively. All of the patients, including the controls, were administered 800mg/day of 5'-DFUR (Furtulon(R)) orally from the fourth week postoperatively. Thirty-two patients were enrolled and 24 of them were subjected to analysis. There were six patients in the control group, five in the 2mg group, six in the 4mg group and seven in the 8mg group. From the above results, it was concluded that the optimal dose of lentinan for advanced colon cancer patients is 8mg/week. (In a pre-clinical study, the incidence of adverse reactions tended to be high over 10mg/week, although they were not serious).
Therefore, it is assumed that a higher dose than that currently used for gastric cancer (1 mg/week) is required to treat colon cancer. According to basic studies, a significantly better effect can be obtained with both preoperative and postoperative administrations of lentinan than with only preoperative or postoperative administration (Kimura, Koyanagi et al., 1996) . It can be assumed that the increase of T-lymphocytes contact with cancer reported on the importance of microscopic emperipolesis when they detected "CD8-positive lymphocytes within cancer nests". Lentinan increases the response to IL-2 by enhancing the expression of IL-2 receptors on lymphocytes, but it is not able to promote IL-2 production Hamuro, Takatsuki et al., 1994) .
Therefore, concomitant use of IL-2 is essential in advanced cancer patients with a reduced IL-2 production capacity.
Study II: Lentinan plus IL-2 Based on the above results, we performed a clinical trial in which both lentinan and IL-2 were administered to patients with advanced colon cancer from 1996 through 1998. The subjects fulfilled the same criteria as those in the first trial. The patients were below 75 years of age with Dukes B or C advanced colon cancer which could be treated with curative surgery. They were divided into three groups: a control group, a lentinan (8 mg) plus low-dose IL-2 (100,000 JRU) group and a lentinan (8mg) plus high-dose IL-2 It has been reported that the Th1/Th2 balance is impaired in cancer patients, Th1
activity become downregulation and Th2 cells tend to become predominant. In recent years, both in vitro and in vivo studies have shown that cytokines similar to Th1/Th2 cytokines are also secreted by both CD4 and CD8 cells, and they are known as Tc1 and Tc2 Mosmann, Sad, 1996; Mosmann, Li et al., 1997) The above results indicate that not only the Th1/Th2 balance but also the Tc1/Tc2 balance is impaired in cancer patients. When the immune function of cancer patients is studied, it is necessary to consider both the Th1/Th2 balance and also Tc1 activity. Immunotherapy which includes IL-2 may increase Tc1 activity in association with improvement of the Th1/Th2 balance and lead to Te1 predominance. This is considered to be important with respect to the development of cachexia as well as the development of resistance to chemotherapy and immunotherapy in cancer patients, i. e., improving the Th1/Th2 balance is a key to improvement of the response to treatment.
Future prospects Yoshino, Hazama et al., (1998) reported that IL-12 (p70), which plays an important role in the induction of the differentiation of T cells from Th0 to Th1, is increased by the administration of lentinan, while the Th2 cytokine IL-10 is reduced.
They reported that it should be possible to modulate the Th1/Th2 balance by administration of OK-432 (a multiple cytokine inducer) after administration of lentinan (Yoshino, Hazama et al., 1998) . Hamuro and Murata (1998) (Hamuro, Murata, 1998 were examined using this experimental system, the growth of colon 26 tumors in the cecal wall was inhibited dose-dependently by PSK. In addition, systemic immunosuppression was alleviated and TGF-B, which is considered to be the main circulating inhibitory factor, was significantly reduced when compared with the untreated group (Harada. Matsunaga et al., 1995 .
The above reports indicate the new approaches being taken in basic research on conventional immunotheraputic agents. In the future, it is expected investigations from various aspects, including the analysis of responders and non-responders, may lead to new clinical applications for immunotherapy.
